Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States

References

• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–6249s.
   PubMed Web of Science ®Google Scholar
• von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer. 2008;16:1105–1115.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–1594.
   PubMed Web of Science ®Google Scholar
• Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer. 2008;16:879–889.
   PubMed Web of Science ®Google Scholar
• von Moos R, Body JJ, Egerdie B, et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer. 2016;24:1327–1337.
   PubMed Web of Science ®Google Scholar
• Harris K, Chow E, Zhang L, et al. Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastases. Eur J Cancer. 2009;45:2510–2518.
   PubMed Web of Science ®Google Scholar
• Body JJ, Chevalier P, Gunther O, et al. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ. 2013;16:539–546.
   PubMedGoogle Scholar
• Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care. 2010;19:755–760.
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16:693–702.
   PubMed Web of Science ®Google Scholar
• Hechmati G, Cure S, Gouepo A, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16:691–700.
   PubMedGoogle Scholar
• Qian Y, Song X, Zhang K, et al. Short-term disability in solid tumor patients with bone metastases and skeletal-related events. J Med Econ. 2015;18:210–218.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Delea TE, Chung K. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. J Med Econ. 2014;17:223–230.
   PubMedGoogle Scholar
• Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–5139.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–3092.
   PubMed Web of Science ®Google Scholar
• Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92:1869–1876.
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314–3321.
   Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2016;53:75–83.
   PubMed Web of Science ®Google Scholar
• Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368–374.
   PubMed Web of Science ®Google Scholar
• Porta-Sales J, Garzon-Rodriguez C, Llorens-Torrome S, et al. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31:5–25.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 3.2013 [Internet]. 2016 [cited 2016 Apr 5]. p MS-55–MS-57. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2012;23:vii139–154.
   PubMed Web of Science ®Google Scholar
• Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221–1227.
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin. 2008;24:3063–3072.
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, et al. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6:e010352.
   PubMed Web of Science ®Google Scholar
• Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res. 2006;12:6236s–6242s.
   PubMed Web of Science ®Google Scholar
• Chung KC, Barlev A, Braun AH, et al. Assessing analgesic use in patients with advanced cancer: development of a new scale – the Analgesic Quantification Algorithm. Pain Med. 2014;15:225–232.
   PubMed Web of Science ®Google Scholar
• Arellano J, Hauber AB, Mohamed AF, et al. Physicians’ preferences for bone metastases drug therapy in the United States. Value Health. 2015;18:78–83.
   PubMed Web of Science ®Google Scholar
• Qian Y, Arellano J, Hauber AB, et al. Patient, caregiver, and nurse preferences for treatments for bone metastases from solid tumors. Patient. 2016;9:323–333.
   Google Scholar
• Hernandez RK, Adhia A, Wade SW, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol. 2015;7:335–345.
   PubMed Web of Science ®Google Scholar
• von Moos R, Body JJ, Rider A, et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol. 2018;11:1–9.
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380.
   PubMed Web of Science ®Google Scholar
• Wood R, Paoli CJ, Hays RD, et al. Evaluation of the consumer assessment of healthcare providers and systems in-center hemodialysis survey. Clin J Am Soc Nephrol. 2014;9:1099–1108.
   PubMed Web of Science ®Google Scholar